Inhibition of the mTORC Pathway in the Antiphospholipid Syndrome

New England Journal of Medicine

Volumn 371, Issue 16, 2014, Pages 1553-1555

  Van Laecke, Steven ^a   Nagler, Evi V ^a   Vanholder, Raymond ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; VON WILLEBRAND FACTOR; IMMUNOSUPPRESSIVE AGENT; PHOSPHOLIPID ANTIBODY; RAPAMYCIN; TARGET OF RAPAMYCIN KINASE; ALPHA2 GLYCOPROTEIN; CARDIOLIPIN ANTIBODY; PROTEIN KINASE B; ALPHA2 GLYCOPROTEIN I ANTIBODY; ANTIBODY; LUPUS ANTICOAGULANT; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ANTIPHOSPHOLIPID SYNDROME; ENZYME ACTIVATION; ENZYME INHIBITION; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; KIDNEY GRAFT; LETTER; PROTEIN BLOOD LEVEL; RISK FACTOR; VASCULAR LESION; VENOUS THROMBOEMBOLISM; DRUG ANTAGONISM; FEMALE; MALE; METABOLISM; NOTE; VASCULAR ENDOTHELIUM; ANTIBODY SPECIFICITY; ANTIBODY TITER; ANTICOAGULANT THERAPY; BLOOD SAMPLING; DEEP VEIN THROMBOSIS; DRUG EFFICACY; ENDOTHELIUM CELL; ENZYME PHOSPHORYLATION; IMMUNOFLUORESCENCE TEST; IN VITRO STUDY; IN VIVO STUDY; KIDNEY POLYCYSTIC DISEASE; RISK ASSESSMENT; TUBEROUS SCLEROSIS; FIBRINOLYTIC THERAPY; LUPUS VULGARIS; THROMBOSIS;

ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84908073165     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1410247     Document Type: Letter

References (5)

1. Canaud G, Bienaimé F, Tabarin F, et al. Inhibition of the mTORC pathway in the antiphospholipid syndrome. N Engl J Med 2014;371:303-12.
2. Austin SK, Starke RD, Lawrie AS, Cohen H, Machin SJ, Mackie IJ. The VWF/ADAMTS13 axis in the antiphospholipid syndrome: ADAMTS13 antibodies and ADAMTS13 dysfunction. Br J Haematol 2008;141:536-44.
3. Baas MC, Gerdes VE, Ten Berge IJ, et al. Treatment with everolimus is associated with a procoagulant state. Thromb Res 2013;132:307-11.
4. Verhave JC, Tagalakis V, Suissa S, Madore F, Hébert MJ, Cardinal H. The risk of thromboembolic events in kidney transplant patients. Kidney Int 2014;85:1454-60.
5. Ahya VN, McShane PJ, Baz MA, et al. Increased risk of venous thromboembolism with a sirolimus-based immunosuppression regimen in lung transplantation. J Heart Lung Transplant 2011;30:175-81.